Know Cancer

or
forgot password

Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.


N/A
18 Years
80 Years
Open (Enrolling)
Female
Ovarian Cancer, Peritoneal Metastases

Thank you

Trial Information

Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.


Inclusion Criteria:



- Histologically confirmed ovarian, primary peritoneal or fallopian tube cancer stage
III or IV

- Scheduled to receive neoadjuvant chemotherapy (carboplatin/cisplatin)with planned
debulking surgery.

Exclusion Criteria:

- Life expectancy of less than 6 months

- MRI contraindications

- Low grade or heavily calcified disease

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Development of a Quantitative Imaging Biomarker for Evaluating Ovarian Cancer Metastases and Assessment of its Potential in Monitoring Treatment Response.

Outcome Description:

Diffusion-weighted magnetic resonance imaging (DW-MRI) for visualising peritoneal metastases will be developed.Reproducibility will be assessed in a multi-centre setting across multiple vendor platforms and field strengths by comparing 2 baseline scans per person and plotting absolute difference in ADC against mean of the 2 measurements.Biological validation will be achieved by correlating scan data (ADC change) following chemotherapy with histology of the tumour(amount of cell death) at surgery.

Outcome Time Frame:

4.0 years

Safety Issue:

No

Principal Investigator

Nandita deSouza, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

ICR

Authority:

United Kingdom: Research Ethics Committee

Study ID:

11/LO/1598 CCR3694

NCT ID:

NCT01505829

Start Date:

August 2012

Completion Date:

December 2015

Related Keywords:

  • Ovarian Cancer
  • Peritoneal Metastases
  • Neoplasm Metastasis
  • Ovarian Neoplasms

Name

Location